title: New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies.
abstract: MMP intervention strategies have met with limited clinical success due to severe toxicities. In particular, treatment with broad-spectrum MMP-inhibitors (MMPIs) caused musculoskeletal pain and inflammation. Selectivity may be essential for realizing the clinical potential of MMPIs. Here we review discoveries pinpointing membrane-bound MMPs as mediators of mechanisms underlying cancer and inflammation and as possible therapeutic targets for prevention/treatment of these diseases. We discuss strategies to target these therapeutic proteases using highly selective inhibitory agents (i.e., human blocking antibodies) against individual membrane-bound MMPs.
authors.affiliation: Merck Serono S.A., 9 Chemin des Mines, Case postale 54, 1211 Geneva 20, Switzerland.
authors.forename: Laetitia
authors.initials: L
authors.lastname: Devy
authors.forename: Daniel T
authors.initials: DT
authors.lastname: Dransfield